Investors Alert: Humacyte Faces Class Action Lawsuit Over Misleading Statements

LOS ANGELES, Nov. 29, 2024 /PRNewswire/ — The Schall Law Firm, a national firm focused on shareholder rights litigation, announces a class action lawsuit against Humacyte, Inc. (“Humacyte” or “the Company”) HUMA for alleged violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5 as outlined by the U.S. Securities and Exchange Commission.

Investors who acquired Humacyte securities between May 10, 2024, and October 17, 2024 (the “Class Period”) should contact the firm by January 17, 2025.

If you are a shareholder who has experienced a loss, click here to participate.

For more information, reach out to Brian Schall of the Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335. You can also contact us through our website at www.schallfirm.com, or via email at bschall@schallfirm.com.

The class has not yet been certified. Until certification occurs, you are not represented by an attorney. If you choose not to participate, you will remain an absent class member.

The Complaint alleges that Humacyte made false and misleading statements. Allegedly, the Company failed to follow good manufacturing practices, including necessary microbial testing at its facility in Durham, North Carolina. Consequently, the FDA’s review of the Company’s Biologic License Application (BLA) will be delayed while these manufacturing issues are addressed. This raises concerns about the FDA’s timely approval of the acellular tissue engineered vessel (“ATEV”) for vascular trauma. Based on these issues, Humacyte’s public statements during the class period were claimed to be false and misleading, causing investor losses when the truth emerged.

Join the case to recover your losses.

The Schall Law Firm represents investors globally and specializes in securities class action lawsuits and shareholder rights cases.

This press release may be considered Attorney Advertising in certain jurisdictions under applicable laws and ethical rules.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

View original content to download multimedia: here

SOURCE The Schall Law Firm